Overview

Testosterone Replacement in Metabolic Syndrome and Inflammation

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Hypogonadism (HG) frequently complicates the Metabolic Syndrome (MetS), whether testosterone replacement (TRT) is beneficial has not been clearly ascertained. This study was designed to address the effects of TRT on insulin resistance, body composition and pro-inflammatory status in naïve patients with MetS and HG.
Phase:
Phase 4
Details
Lead Sponsor:
University of Roma La Sapienza
Treatments:
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate